Literature DB >> 10405947

The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario.

K P White1, M Speechley, M Harth, T Ostbye.   

Abstract

OBJECTIVE: To estimate the point prevalence of fibromyalgia syndrome (FM) among noninstitutionalized Canadian adults; and to assess the effect of demographic variables on the odds of having FM.
METHODS: A screening questionnaire was administered via telephone to a random community sample of 3395 noninstitutionalized adults residing in London, Ontario. Individuals screening positive were invited to be examined by a rheumatologist to confirm or exclude FM using the 1990 American College of Rheumatology classification criteria.
RESULTS: One hundred confirmed cases of FM were identified, of whom 86 were women. Mean age among FM cases was 49.2 years among women, 39.3 years among men (p < 0.02). FM affects an estimated 4.9% (95% CI 4.7%, 5.1%) of adult women and 1.6% (1.3%, 1.9%) of adult men in London, for a female to male ratio of roughly 3 to one. In women, prevalence rises steadily with age from < 1% in women aged 18-30 to almost 8% in women 55-64. Thereafter, it declines. The peak prevalence in men also appears to be in middle age (2.5%; 1.1%, 5.7%). FM affects 3.3% (3.2%, 3.4%) of noninstitutionalized adults in London. Female sex, middle age, less education, lower household income, being divorced, and being disabled are associated with increased odds of having FM.
CONCLUSION: FM is a common musculoskeletal disorder among Canadian adults, especially among women and persons of lower socioeconomic status.

Entities:  

Mesh:

Year:  1999        PMID: 10405947

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  102 in total

1.  Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement.

Authors:  O Zachrisson; P Colque-Navarro; C G Gottfries; B Regland; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-20       Impact factor: 3.267

2.  Prevalence of chronic widespread pain and fibromyalgia syndrome: a Korean hospital-based study.

Authors:  Cheolhwan Kim; Hyejin Kim; Jongkwan Kim
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

3.  Pain characteristics and pain catastrophizing in incarcerated women with chronic pain.

Authors:  Beth D Darnall; Elizabeth Sazie
Journal:  J Health Care Poor Underserved       Date:  2012-05

Review 4.  Worldwide epidemiology of fibromyalgia.

Authors:  Luiz Paulo Queiroz
Journal:  Curr Pain Headache Rep       Date:  2013-08

Review 5.  Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria.

Authors:  John McBeth; Matthew R Mulvey
Journal:  Nat Rev Rheumatol       Date:  2012-01-24       Impact factor: 20.543

6.  A randomized, double-blind, placebo-controlled clinical trial using a low-frequency magnetic field in the treatment of musculoskeletal chronic pain.

Authors:  Alex W Thomas; Karissa Graham; Frank S Prato; Julia McKay; Patricia Morley Forster; Dwight E Moulin; Sesh Chari
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

7.  Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.

Authors:  Kathleen C Light; Edith E Bragdon; Karen M Grewen; Kimberly A Brownley; Susan S Girdler; William Maixner
Journal:  J Pain       Date:  2009-05       Impact factor: 5.820

8.  Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

Authors:  Akiko Okifuji; David H Bradshaw; Chrisana Olson
Journal:  Clin Rheumatol       Date:  2009-01-27       Impact factor: 2.980

9.  [Prevalence of chronic pain in Germany. A representative survey of the general population].

Authors:  W Häuser; G Schmutzer; A Hinz; A Hilbert; E Brähler
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

10.  Implications of gender in chronic Lyme disease.

Authors:  Gary P Wormser; Eugene D Shapiro
Journal:  J Womens Health (Larchmt)       Date:  2009-06       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.